Radionuclide diagnosis and therapy of thyroid cancer: current status report.
Thyroid cancer is uncommon, with an incidence of 10,300 new patients each year and a mortality of 1,100 patients each year. Patient survival correlates with many factors, including tumor pathology, age, primary lesion size, distant metastases, extent of surgery, and radioiodine therapy. Deaths from thyroid cancer may occur many years after diagnosis, and such an indolent course has hampered the analysis of the multiple treatment programs advocated. Thyroid imaging continues to play an important role in the initial detection and follow-up management of thyroid cancer, but the search for a specific tracer for the primary lesion continues. The complementary role of serum thyroglobulin and radioiodine in the follow-up of the thyroidectomized patient is discussed. Radioiodine therapy has proven effectiveness in those patients with radioiodine-avid distant metastases and/or regional metastases. Whether radioiodine ablation of residual thyroid bed activity is beneficial remains controversial.
Freitas
J E
JE
Gross
M D
MD
Ripley
S
S
Shapiro
B
B
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000628:therapy; D000328:Adult; D002291:Carcinoma, Papillary / Q000000981:diagnostic imaging / Q000628:therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000556:secondary; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D013670:Sodium Pertechnetate Tc 99m; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy; D013965:Thyroidectomy
D007457:Iodine Radioisotopes; D013670:Sodium Pertechnetate Tc 99m